Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1995-06-01
1997-09-16
Ulm, John
Drug, bio-affecting and body treating compositions
Lymphokine
514 2, 514261, 514474, 514550, 530351, C07K 14525, A61K 3819
Patent
active
056677766
ABSTRACT:
Damage to cells, tissue and other body parts in a mammalian host may be treated by using a tumor necrosis factor in conjunction with at least one biological modifier, which may be a free radical scavenger or a metabolic inhibitor. The biological modifier is preferably uric acid, buthionine sulphoximine, vitamin C, aspirin, or nordihydroguaiaretic acid. Such a combination may be used to treat, for example, cancer, infectious diseases, and damage caused by radiation therapy, high oxygen tension, and chemotherapy.
REFERENCES:
patent: 4645830 (1987-02-01), Yasushi et al.
patent: 4762705 (1988-08-01), Rubin
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 4980160 (1990-12-01), Goldberg et al.
patent: 4985241 (1991-01-01), Zimmerman et al.
patent: 5002879 (1991-03-01), Bowlin et al.
patent: 5021239 (1991-06-01), Garnick
patent: 5508031 (1996-04-01), Zimmermann et al.
Dayer et al., "Cachectin/Tumor Necrosis Factor Stimulates Collagenase and Prostaglandin E.sub.2 Production by Human Synovial Cells and Dermal Fibroblasts," J. Exp. Med., 162:2163-2168 (Dec., 1985).
Dinarello et al., "Tumor Necrosis Factor (Cachectin) is an Endogenous Pyrogen and Induces Production of Interleukin 1," J. Exp. Med., 163:1433-1450 (Jun., 1986).
Adams et al., "Plasma Glutathione and Glutathione Disulfide in the Rat: Regulation and Response to Oxidative Stress," J. Pharmacol. Exp. Ther., 227(3):749-754 (1983).
Alexander et al., "Synergistic Enhancement by Tumor Necrosis Factor of in Vitro Cytotoxicity from Chemotherapeutic Drugs Targeted at DNA Topisomerase II," Cancer Research, 47:2403-2406 (May 1, 1987).
Almqvist et al., "Treatment of Experimental Canine Endotoxin Shock with Ibuprofen, a Cyclooxygenase Inhibitor," Circulatory Shock, 13:227-232 (1984).
Ames et al., "Uric acid provides an antioxidant defense in humans against oxidant-and radical-caused aging and cancer: A hypothesis," PNAS (USA), 78(11):6858-6862 (Nov., 1981).
Andrews et al., "Differential Potentiation of Alkylating and Platinating Agent Cytotoxicity in Human Ovarian Carcinoma Cells by Glutathione Depletion," Cancer Res., 45:6250-6253 (Dec., 1985).
Aoki et al., "Indomethacin Augments Inhibitory Effect of Interferons on Lymphoproliferative Response," Immunology Letters, 7:321-24 (1984).
Arrick et al., "Inhibition of Glutathione Synthesis Augments Lysis of Murine Tumor Cells by Sulfhydryl-reactive Antineoplastics," J. Clin. Invest., 71(2):258-267 (Feb., 1983).
Aune and Pogue, "Inhibition of Tumor Cell Growth by Interferon-.gamma. is Mediated by Two Distinct Mechanisms Dependent upon Oxygen Tension: Induction of Tryptophan Degradation and Depletion of Intracellular Nicotinamide Adenine Dinucleotide", J. Clin. Invest., 84:863-875 (Sep., 1989).
Bachwich et al., "Tumor Necrosis Factor Stimulates Interleukin-1 and Prostaglandin E.sub.2 Production in Resting Macrophages," Biochemical and Biophysical Research Communications, 136:94-101 (1986).
Badwey and Karnovsky, "Active Oxygen Species And The Functions Of Phagocytic Leukocytes," Ann. Rev. Biochem., 49:695-726 (1980).
Balkwill et al., "Human Tumor Xenografts Treated with Recombinant Human Tumor Necrosis Factor Alone or in Combination with Interferons," Cancer Research, 46:3990-3993 (1986).
Bollag, "Retinoids and Interferon: a new promising combination?" British J. of Haematol., 79(Suppl. 1):87-91 (1991).
Borden, et al., "Lymphokines and Cytokines as Cancer Treatment Immunotherapy Realized," Cancer (Supplement), 65(3):800-814 (Feb. 1, 1990).
Bus and Gibson, "Lipid Peroxidation And Its Role In Toxicology," Rev. Biochm. Toxicol., (Hodgson et al., Eds.)., Elsevier, North Holland, pp. 125-149 (1979).
Cerutti et al., "Membrane-Mediated Chromosomal Damage," Genes And Proteins In Oncogenesis, (Academic Press, NY)., pp. 55-67 (1983).
Chun et al., "Enhancement of Cytotoxic Activity of Natural Killer Cells by Interleukin 2, and Antagonism between Interleukin 2 and Adenosine Cyclic Monophosphate," Scand. J. Immunol. 22:375-81 (1985).
Clark, et al., "Tumor Necrosis Factor and Reactive Oxygen Species: Implications for Free Radical-Induced Tissue Injury," Upjon Symposium/Oxygen Radicals, 122-129 (Apr., 1987).
Crook et al., "Glutathione Depletion as a Determinant of Sensitivity of Human Leukemia Cells to Cyclophosphamide," Cancer Res., 46:5035-5038 (1986).
Das et al., "Free Radicals as Possible Mediators of the Actions of Interferon," J. Free Radicals in Biology and Medicine, 2:183-188 (1986).
DiGuiseppi et al., "The Toxicology Of Molecular Oxygen," CRC Crit. Rev. Toxicol., 12:315-342 (1984).
Dorr et al., "Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR).-sulfoximine on human and murine tumor cells," Invest. New Drugs, 4:305-313 (1986).
Dreno et al., "The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of Interferon-.alpha.2a and etretinate," British J. of Dermatol., 125:456-459 (1991).
Ferrante, "Tumor Necrosis Factor Alpha Potentiates Neutrophil Antimicrobial Activity: Increased Fungicidal Activity against Torulopsis glabrata and Candida albicans and Associated Increases in Oxygen Radical Production and Lysosomal Enzyme Release," Infect. Immunity, 57(7):2115-2122 (Jul., 1989).
Freund and Pick, "The Mechanism of Action of Lymphokines IX. The Enzymatic Basis of Hydrogen Peroxide Production by Lymphokine-Activated Macrophages," J. Immunol., 137(4):1312-1318 (Aug. 15, 1986).
Fridovich, "The Biology of Oxygen Radicals," Science, 201:875-880 (1978).
Front et al., "Administered Dose and Tumor Dose of Bleomycin Labeled with Cobalt-57 in Mice and Men," J. Nuclear Med., 31(11):1784-1790 (Nov., 1990).
Gerberick et al., "Relationships Between Pulmonary Inflammation, Plasma Transudation, and Oxygen Metabolite Secretion by Alveolar Macrophages," J. Immunol., 137(1):114-121 (Jul. 1, 1986).
Ghezzi et al., "Role of Reactive Oxygen Intermediates in the Interferon-mediated Depression of Hepatic Drug Metabolism and Protective Effect of N-Acetylcysteine in Mice," Cancer Res. 45:3444-3447 (Aug., 1985).
Godal et al., "Pharmacological studies of ricin in mice and humans," Cancer Chemother. Pharmacol., 13:157-163 (1984).
Green et al., "Potentiation of Melphalan Cytotoxicity in Human Ovarian Cancer Cell Lines by Glutathione Depletion," Cancer Res., 44:5427-5431 (1984).
Hamilton et al., "Augmentation of Adriamycin, Melphalan, and Cisplatin Cytotoxicity in Drug-Resistant and Sensitive Human Ovarian Carcinoma Cell Lines by Buthionine Sulfoximine Mediated Glutathione Depletion," Biochem. Pharmacol., 34(14):2583-2586 (Jul., 1985).
Hauser et al., "Manipulation of Oxygen Radical-scavenging Capacity in Mice Alters Host Sensitivity to Tumor Necrosis Factor Toxicity but Does Not Interfere with Its Antitumor Efficacy," Cancer Res., 50:3503-3508 (Jun. 15, 1990).
Hill et al., "Granulocyte-macrophage colony-stimulating factor inhibits tumor growth," Br. J. Surg., 80:1543-1546 (Dec., 1993).
Hird, "Immunotherapy with Monoclonal Antibodies," in Genes and Cancer, D. Carney & K. Sikora, Eds., New York: John Wiley & Sons (1990), pp. 183-189.
Hodgkiss and Middleton, "Effects of Glutathione Depletion Using Buthionine Sulphoximine on the Cytotoxicity of Nitroaramoatic Compounds in Mammalian Cells In Vitro," Biochem. Pharmacol., 34:2175-2178 (1985).
Itri, "The Interferons," Cancer (Supplement), 70(4):940-945 (Aug. 15, 1992).
Iwasaka et al., "Antitumor Effects of Human Recombinant Interferon-.gamma. and Tumor Necrosis Factor On Five Cervical Adenocarcinoma Cell Lines, in Vivo and in Vitro," Gynecologic Oncology, 42:39-43 (1991).
Jiang et al., "Potentiation of IL-2-Induced T-Cell Proliferation by Retinoids," Int. J. Immunopharmac., 14(2):195-204 (1992).
Johnston, "The Production of Superoxide by Cultured Macrophages," in CRC Handbook of Methods for Oxygen Radical Research, pp. 373-377 (1982).
Jones, "Free Radicals in Immunological Killing: The Case of Tumor Necrotising Factor (TNF)", Med. Hypotheses 21(3):267-271 (1986).
Kawakami et al., "Cachectin/TNF as well as Interleukin-1 Induces Prostacyclin Synthesis in Cultures Vascular Endothelial Cells," Biochemical and Biophysical Research Communications, 141:482-48
Marafino, Jr. Benedict J.
Zimmerman Robert
Blackburn Robert P.
Chiron Corporation
Gass David A.
Mertz Prema
Savereide Paul B.
LandOfFree
Treatment for biological damage using tumor necrosis factor and does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment for biological damage using tumor necrosis factor and , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment for biological damage using tumor necrosis factor and will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-216192